Drug Profile
Research programme: interleukin-17 receptor antagonists - HitGen
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator HitGen
- Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Macrocyclic compounds
- Mechanism of Action Interleukin 17 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma; Multiple sclerosis; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Asthma in China (PO)
- 28 Apr 2021 No recent reports of development identified for research development in Multiple-sclerosis in China (PO)
- 28 Apr 2021 No recent reports of development identified for research development in Psoriasis in China (PO)